Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
0.4100
-0.0051 (-1.23%)
Nov 7, 2025, 12:01 PM EST - Market open
Can-Fite BioPharma Revenue
Can-Fite BioPharma had revenue of $202.00K in the half year ending June 30, 2025, a decrease of -48.47%. This brings the company's revenue in the last twelve months to $560.00K, down -16.04% year-over-year. In the year 2024, Can-Fite BioPharma had annual revenue of $674.00K, down -9.29%.
Revenue (ttm)
$560.00K
Revenue Growth
-16.04%
P/S Ratio
27.97
Revenue / Employee
$112,000
Employees
5
Market Cap
15.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 674.00K | -69.00K | -9.29% |
| Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
| Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
| Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
| Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CANF News
- 2 months ago - Can-Fite Reports H1 2025 Financial Results and Clinical Update - GlobeNewsWire
- 3 months ago - Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone - GlobeNewsWire
- 3 months ago - Can-Fite Announces Up To $15.0 Million Public Offering - GlobeNewsWire
- 3 months ago - Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia - GlobeNewsWire
- 7 months ago - Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients - GlobeNewsWire
- 7 months ago - Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 8 months ago - Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market - GlobeNewsWire
- 8 months ago - Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson - GlobeNewsWire